{"pmid":32341141,"title":"Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 Using Real Time Reverse Transcription PCR.","text":["Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 Using Real Time Reverse Transcription PCR.","The global COVID-19 pandemic has resulted in a worldwide shortage of viral transport media and raised questions about specimen stability. The objective of this study was to determine the stability of SARS-CoV-2 virus RNA in specimen transport media under various storage conditions. Transport medium tested included: VCM, UTM(R)-RT, ESwab, M4 and saline (0.9% NaCl). Specimen types tested included Nasopharyngeal/Oropharyngeal (NP/OP) swabs in the above transport media, bronchoalveolar lavage (BAL) and Sputum. A high-titer SARS-CoV-2 remnant patient specimen was spiked into pooled SARS-CoV-2 RNA-negative specimen remnants for the various media types. Aliquots of samples were stored at 18 degrees C to 25 degrees C, 2 degrees C to 8 degrees C and -10 degrees C to -30 degrees C and then tested at time points up to 14 days. Specimens consistently yielded amplifiable RNA with mean Ct differences of <3 over the various conditions assayed, thus supporting the use and transport of alternative collection media and specimen types under a variety of temperature storage conditions.","J Clin Microbiol","Rogers, Amy A","Baumann, Russell E","Borillo, Gwynngelle A","Kagan, Ron M","Batterman, Hollis J","Galdzicka, Marzena","Marlowe, Elizabeth M","32341141"],"abstract":["The global COVID-19 pandemic has resulted in a worldwide shortage of viral transport media and raised questions about specimen stability. The objective of this study was to determine the stability of SARS-CoV-2 virus RNA in specimen transport media under various storage conditions. Transport medium tested included: VCM, UTM(R)-RT, ESwab, M4 and saline (0.9% NaCl). Specimen types tested included Nasopharyngeal/Oropharyngeal (NP/OP) swabs in the above transport media, bronchoalveolar lavage (BAL) and Sputum. A high-titer SARS-CoV-2 remnant patient specimen was spiked into pooled SARS-CoV-2 RNA-negative specimen remnants for the various media types. Aliquots of samples were stored at 18 degrees C to 25 degrees C, 2 degrees C to 8 degrees C and -10 degrees C to -30 degrees C and then tested at time points up to 14 days. Specimens consistently yielded amplifiable RNA with mean Ct differences of <3 over the various conditions assayed, thus supporting the use and transport of alternative collection media and specimen types under a variety of temperature storage conditions."],"journal":"J Clin Microbiol","authors":["Rogers, Amy A","Baumann, Russell E","Borillo, Gwynngelle A","Kagan, Ron M","Batterman, Hollis J","Galdzicka, Marzena","Marlowe, Elizabeth M"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341141","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00708-20","locations":["UTM(R)-RT"],"e_drugs":["Sodium Chloride"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495100387330,"score":9.490897,"similar":[{"pmid":32405270,"pmcid":"PMC7219422","title":"Detection of SARS-CoV-2 is comparable in clinical samples preserved in saline or viral transport media.","text":["Detection of SARS-CoV-2 is comparable in clinical samples preserved in saline or viral transport media.","As the COVID-19 pandemic sweeps across the world, the availability of viral transport media (VTM) has become severely limited, contributing to delays in diagnosis and rationing of diagnostic testing. Given that SARS-CoV-2 viral RNA has demonstrated stability, we posited that phosphate buffered saline (PBS) may be a viable transport medium, as an alternative to VTM), for clinical qPCR testing. We assessed the intra- and inter-individual reliability of SARS-CoV-2 qPCR in clinical endotracheal secretion samples transported in VTM or PBS, evaluating the stability of the RT-qPCR signal for three viral targets (N gene, ORF1ab, and S gene) when samples were stored in these media at room temperature for up to 18 hours. We report that using PBS as a transport medium has high intra-and inter-individual reliability, maintains viral stability, and is comparable to VTM in the detection of the three SARS-CoV-2 genes through 18 hours of storage. Our study establishes PBS as a clinically useful medium that can be readily deployed for transporting and short-term preservation of specimens containing SARS-CoV-2. Use of PBS as a transport medium has the potential to increase testing capacity for SARS-CoV-2, aiding more widespread screening and early diagnosis of COVID-19.","J Mol Diagn","Radbel, Jared","Jagpal, Sugeet","Roy, Jason","Brooks, Andrew","Tischfield, Jay","Sheldon, Michael","Bixby, Christian","Witt, Dana","Gennaro, Maria Laura","Horton, Daniel B","Barrett, Emily S","Carson, Jeffrey L","Panettieri, Reynold A Jr","Blaser, Martin J","32405270"],"abstract":["As the COVID-19 pandemic sweeps across the world, the availability of viral transport media (VTM) has become severely limited, contributing to delays in diagnosis and rationing of diagnostic testing. Given that SARS-CoV-2 viral RNA has demonstrated stability, we posited that phosphate buffered saline (PBS) may be a viable transport medium, as an alternative to VTM), for clinical qPCR testing. We assessed the intra- and inter-individual reliability of SARS-CoV-2 qPCR in clinical endotracheal secretion samples transported in VTM or PBS, evaluating the stability of the RT-qPCR signal for three viral targets (N gene, ORF1ab, and S gene) when samples were stored in these media at room temperature for up to 18 hours. We report that using PBS as a transport medium has high intra-and inter-individual reliability, maintains viral stability, and is comparable to VTM in the detection of the three SARS-CoV-2 genes through 18 hours of storage. Our study establishes PBS as a clinically useful medium that can be readily deployed for transporting and short-term preservation of specimens containing SARS-CoV-2. Use of PBS as a transport medium has the potential to increase testing capacity for SARS-CoV-2, aiding more widespread screening and early diagnosis of COVID-19."],"journal":"J Mol Diagn","authors":["Radbel, Jared","Jagpal, Sugeet","Roy, Jason","Brooks, Andrew","Tischfield, Jay","Sheldon, Michael","Bixby, Christian","Witt, Dana","Gennaro, Maria Laura","Horton, Daniel B","Barrett, Emily S","Carson, Jeffrey L","Panettieri, Reynold A Jr","Blaser, Martin J"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405270","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jmoldx.2020.04.209","topics":["Diagnosis"],"weight":1,"_version_":1666802845455745024,"score":607.0769},{"pmid":32405257,"pmcid":"PMC7219399","title":"Validation of SARS-CoV-2 detection across multiple specimen types.","text":["Validation of SARS-CoV-2 detection across multiple specimen types.","Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused considerable disruption across the world, resulting in more than 235,000 deaths since December 2019. SARS-CoV-2 has a wide tropism and detection of the virus has been described in multiple specimen types, including various respiratory secretions, cerebrospinal fluid, and stool. Objective: To evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types. Study Design We compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected in viral transport medium (VTM), bronchoalveolar lavage (BAL), sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate buffered saline (PBS), and Hanks' Balanced Salt Solution (HBSS). Initial limits of detection (LoD) were subsequently narrowed to confirm an LoD for each specimen type and target gene. Results: LoDs were established using a modified CDC-based laboratory developed test and ranged from a mean CT cut-off of 33.8-35.7 (10-20 copies/reaction) for the N1 gene target, and 34.0-36.2 (1-10 copies/reaction) for N2. Alternatives to VTM such as PBS and HBSS had comparable LoDs. The N2 gene target was found to be most sensitive in CSF. Conclusion: A modified CDC-based laboratory developed test is able to detect SARSCoV- 2 accurately with similar sensitivity across all sample types tested.","J Clin Virol","Perchetti, Garrett A","Nalla, Arun K","Huang, Meei-Li","Zhu, Haiying","Wei, Yulun","Stensland, Larry","Loprieno, Michelle A","Jerome, Keith R","Greninger, Alexander L","32405257"],"abstract":["Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused considerable disruption across the world, resulting in more than 235,000 deaths since December 2019. SARS-CoV-2 has a wide tropism and detection of the virus has been described in multiple specimen types, including various respiratory secretions, cerebrospinal fluid, and stool. Objective: To evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types. Study Design We compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected in viral transport medium (VTM), bronchoalveolar lavage (BAL), sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate buffered saline (PBS), and Hanks' Balanced Salt Solution (HBSS). Initial limits of detection (LoD) were subsequently narrowed to confirm an LoD for each specimen type and target gene. Results: LoDs were established using a modified CDC-based laboratory developed test and ranged from a mean CT cut-off of 33.8-35.7 (10-20 copies/reaction) for the N1 gene target, and 34.0-36.2 (1-10 copies/reaction) for N2. Alternatives to VTM such as PBS and HBSS had comparable LoDs. The N2 gene target was found to be most sensitive in CSF. Conclusion: A modified CDC-based laboratory developed test is able to detect SARSCoV- 2 accurately with similar sensitivity across all sample types tested."],"journal":"J Clin Virol","authors":["Perchetti, Garrett A","Nalla, Arun K","Huang, Meei-Li","Zhu, Haiying","Wei, Yulun","Stensland, Larry","Loprieno, Michelle A","Jerome, Keith R","Greninger, Alexander L"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405257","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104438","keywords":["bal","csf","sars-cov-2","coronavirus","sensitivity","specimen type"],"topics":["Diagnosis"],"weight":1,"_version_":1666802845614080001,"score":452.88293},{"pmid":32470887,"title":"Validation of SARS-CoV-2 detection across multiple specimen types.","text":["Validation of SARS-CoV-2 detection across multiple specimen types.","BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused considerable disruption across the world, resulting in more than 235,000 deaths since December 2019. SARS-CoV-2 has a wide tropism and detection of the virus has been described in multiple specimen types, including various respiratory secretions, cerebrospinal fluid, and stool. OBJECTIVE: To evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types. Study Design We compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected in viral transport medium (VTM), bronchoalveolar lavage (BAL), sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate buffered saline (PBS), and Hanks' Balanced Salt Solution (HBSS). Initial limits of detection (LoD) were subsequently narrowed to confirm an LoD for each specimen type and target gene. RESULTS: LoDs were established using a modified CDC-based laboratory developed test and ranged from a mean CT cut-off of 33.8-35.7 (10-20 copies/reaction) for the N1 gene target, and 34.0-36.2 (1-10 copies/reaction) for N2. Alternatives to VTM such as PBS and HBSS had comparable LoDs. The N2 gene target was found to be most sensitive in CSF. CONCLUSION: A modified CDC-based laboratory developed test is able to detect SARSCoV- 2 accurately with similar sensitivity across all sample types tested.","J Clin Virol","Perchetti, Garrett A","Nalla, Arun K","Huang, Meei-Li","Zhu, Haiying","Wei, Yulun","Stensland, Larry","Loprieno, Michelle A","Jerome, Keith R","Greninger, Alexander L","32470887"],"abstract":["BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused considerable disruption across the world, resulting in more than 235,000 deaths since December 2019. SARS-CoV-2 has a wide tropism and detection of the virus has been described in multiple specimen types, including various respiratory secretions, cerebrospinal fluid, and stool. OBJECTIVE: To evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types. Study Design We compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected in viral transport medium (VTM), bronchoalveolar lavage (BAL), sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate buffered saline (PBS), and Hanks' Balanced Salt Solution (HBSS). Initial limits of detection (LoD) were subsequently narrowed to confirm an LoD for each specimen type and target gene. RESULTS: LoDs were established using a modified CDC-based laboratory developed test and ranged from a mean CT cut-off of 33.8-35.7 (10-20 copies/reaction) for the N1 gene target, and 34.0-36.2 (1-10 copies/reaction) for N2. Alternatives to VTM such as PBS and HBSS had comparable LoDs. The N2 gene target was found to be most sensitive in CSF. CONCLUSION: A modified CDC-based laboratory developed test is able to detect SARSCoV- 2 accurately with similar sensitivity across all sample types tested."],"journal":"J Clin Virol","authors":["Perchetti, Garrett A","Nalla, Arun K","Huang, Meei-Li","Zhu, Haiying","Wei, Yulun","Stensland, Larry","Loprieno, Michelle A","Jerome, Keith R","Greninger, Alexander L"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470887","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jcv.2020.104438","keywords":["bal","csf","coronavirus","sars-cov-2","sensitivity","specimen type"],"topics":["Diagnosis"],"weight":1,"_version_":1668167110070632448,"score":452.88293},{"pmid":32295895,"title":"Comparison of Copan Eswab and FLOQswab for COVID-19 PCR diagnosis: working around a supply shortage.","text":["Comparison of Copan Eswab and FLOQswab for COVID-19 PCR diagnosis: working around a supply shortage.","On March 16(th) 2020, WHO Director-General stated \"You cannot fight a fire blindfolded. And we cannot stop this [COVID-19] pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case.\" (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at -the-media-briefing-on-covid-19---16-march-2020) This strategy hinges on the availability of appropriate, validated collection and transport systems to ensure preservation of nucleic acids and compatibility with downstream molecular testing - an acute challenge in the current pandemic. We present direct comparison of COVID-19 specimens collected with FLOQswab Nasopharyngeal Swab preserved in universal transport medium (Copan UTM System, Copan, Italy, catalog No.305C), optimized for viral specimens, and flocked regular nylon tip swab preserved in liquid amies (Eswab Collection system, Copan, Italy, catalog No. 480C), optimized for bacterial specimens.","J Clin Microbiol","Vermeiren, Christie","Marchand-Senecal, Xavier","Sheldrake, Elena","Bulir, David","Smieja, Marek","Chong, Sylvia","Forbes, Jessica D","Katz, Kevin","32295895"],"abstract":["On March 16(th) 2020, WHO Director-General stated \"You cannot fight a fire blindfolded. And we cannot stop this [COVID-19] pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case.\" (https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at -the-media-briefing-on-covid-19---16-march-2020) This strategy hinges on the availability of appropriate, validated collection and transport systems to ensure preservation of nucleic acids and compatibility with downstream molecular testing - an acute challenge in the current pandemic. We present direct comparison of COVID-19 specimens collected with FLOQswab Nasopharyngeal Swab preserved in universal transport medium (Copan UTM System, Copan, Italy, catalog No.305C), optimized for viral specimens, and flocked regular nylon tip swab preserved in liquid amies (Eswab Collection system, Copan, Italy, catalog No. 480C), optimized for bacterial specimens."],"journal":"J Clin Microbiol","authors":["Vermeiren, Christie","Marchand-Senecal, Xavier","Sheldrake, Elena","Bulir, David","Smieja, Marek","Chong, Sylvia","Forbes, Jessica D","Katz, Kevin"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295895","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1128/JCM.00669-20","locations":["Copan","Italy","Copan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Nylons"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493293690880,"score":445.2165},{"pmid":32405252,"pmcid":"PMC7217789","title":"Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.","text":["Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.","Background: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. Objective: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. Study design: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. Results: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. Conclusions: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs.","J Clin Virol","Smithgall, Marie C","Scherberkova, Ioana","Whittier, Susan","Green, Daniel A","32405252"],"abstract":["Background: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. Objective: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. Study design: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. Results: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. Conclusions: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs."],"journal":"J Clin Virol","authors":["Smithgall, Marie C","Scherberkova, Ioana","Whittier, Susan","Green, Daniel A"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405252","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104428","keywords":["covid-19","molecular diagnostics","pcr","point of care","sars-cov-2"],"locations":["cobas","Xpert","Xpert","Xpert","Xpert","cobas"],"topics":["Diagnosis"],"weight":1,"_version_":1666802845576331264,"score":406.39502}]}